🔍

Search Results - crohn%27s+disease

2 Results Sort By:
PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)
C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...
Published: 3/13/2025   |   Inventor(s): Philip Alex, Michael Centola, Xuhang Li
Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Crohn's Disease, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Gastroenterology > Ulcerative Colitis, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation, Technology Classifications > Therapeutic Modalities
PNU-120596 and 3-(2,4-dimethoxybenzylidene) Anabaseine (GTS-21) (both nAchRa7 agonists) and Methyllycaconitine (anAchRa7 antagonist), are Highly Effective Drugs in Therapy of Ulcerative Colitis (UC) and Crohn's Disease (CD)
C10382: Breakthrough Therapeutic for Inflammatory Bowel Diseases (IBD)Novelty: This technology identifies a nicotinic acetylcholine receptor isoform (nAChR7) that has a prevalent role in affecting Inflammatory Bowel Disease (IBD), as well as several agonist/antagonists to nAChR7, that are highly effective in both the prevention and therapy of ulcerative...
Published: 3/13/2025   |   Inventor(s): Philip Alex, Michael Centola, Xuhang Li
Keywords(s): Chronic Inflammatory Diseases, Combination, Crohn's disease, Crohn's Disease, Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD), Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Ulcerative Colitis, Ulcerative Colitis (UC)
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology > Crohn's Disease, Clinical and Disease Specializations > Gastroenterology > Inflammatory Bowel Disease, Clinical and Disease Specializations > Gastroenterology > Ulcerative Colitis, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Inflammation, Technology Classifications > Therapeutic Modalities
JHTV Home | Search | Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum